Functional Impairments of Amyloidosis Patients: Physical Therapy Assessment
Abstract
:1. Introduction
2. Materials and Methods
Statistics
3. Results
3.1. Patient Characteristics
3.2. Physical Therapy Assessment
4. Discussion
Study Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations:
Comprehensive Amyloidosis Clinic | CAC |
The Ohio State University | OSU |
Timed Up and Go | TUG |
Light Chain | AL |
Wild-type | ATTRwt |
Hereditary variant | ATTRv |
Multiple Myeloma | MM |
References
- Boudreau, J.; Lagunilla, J.; Kotkiewicz, J. Physical and Edema Therapy Management of Amyloidosis in the Acute Care Setting: A Case Report. Rehabil. Oncol. 2019, 37, E1–E10. [Google Scholar] [CrossRef]
- Shin, S.C.; Robinson-Papp, J. Amyloid neuropathies. Mt. Sinai J. Med. 2012, 79, 733–748. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yarlas, A.; Gertz, M.A.; Dasgupta, N.R.; Obici, L.; Pollock, M.; Ackermann, E.J.; Lovley, A.; Kessler, A.S.; Patel, P.A.; White, M.K.; et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve 2019, 60, 169–175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomás, M.T.; Santa-Clara, M.H.; Monteiro, E.; Baynard, T.; Carnero, E.Á.; Bruno, P.M.; Barroso, E.; Sardinha, L.B.; Fernhall, B. Body composition, muscle strength, functional capacity, and physical disability risk in liver transplanted familial amyloidotic polyneuropathy patients. Clin. Transplant. 2011, 25, E406–E414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sanchorawala, V.; McCausland, K.L.; White, M.K.; Bayliss, M.S.; Guthrie, S.D.; Lo, S.; Skinner, M. A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: Associations with health outcomes over time. Br. J. Haematol. 2017, 179, 461–470. [Google Scholar] [CrossRef] [PubMed]
- Keilani, M.; Kainberger, F.; Pataraia, A.; Hasenöhrl, T.; Wagner, B.; Palma, S.; Cenik, F.; Crevenna, R. Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma. Wien. Klin. Wochenschr. 2019, 131, 567–575. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coleman, E.A.; Coon, S.; Hall-Barrow, J.; Richards, K.; Gaylor, D.; Stewart, B. Feasibility of exercise during treatment for multiple myeloma. Cancer Nurs. 2003, 26, 410–419. [Google Scholar] [CrossRef] [PubMed]
- Karavatas, S.G.; Reicherter, E.A.; White, N.S.A. Physical therapy management of patients with multiple myeloma: Musculoskeletal considerations. Rehabil. Oncol. 2006, 24, 11–16. [Google Scholar] [CrossRef]
- Coelho, T.; Maurer, M.S.; Suhr, O.B. THAOS—The Transthyretin Amyloidosis Outcomes Survey: Initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr. Med. Res. Opin. 2013, 29, 63–76. [Google Scholar] [CrossRef] [PubMed]
- Norkin, C.C.; White, J.D. Measurement of Joint Motion: A Guide to Goniometry, 5th ed.; F.A. Davis Company: Philadelphia, PA, USA, 2017. [Google Scholar]
- Hislop, H.; Avers, D.; Brown, M. Daniels and Worthinghams Muscle Testing: Techniques of Manual Examination and Performance Testing; Elsevier: St. Louis, MO, USA, 2019. [Google Scholar]
- Jones, C.J.; Rikli, R.E.; Beam, W.C. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res. Q. Exerc. Sport 1999, 70, 113–119. [Google Scholar] [CrossRef] [PubMed]
- Shumway-Cook, A.; Brauer, S.; Woollacott, M. Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. Phys. Ther. 2000, 80, 896–903. [Google Scholar] [PubMed] [Green Version]
- Brazier, J.E.; Harper, R.; Jones, N.M.; O’cathain, A.; Thomas, K.J.; Usherwood, T.; Westlake, L. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. Br. Med. J. 1992, 305, 160–164. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chakraborty, R.; Rybicki, L.; Tomer, J.; Samaras, C.J.; Faiman, B.M.; Valent, J.; Majhail, N.S. Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population. Leukemia Lymphoma 2019, 60, 3544–3551. [Google Scholar] [CrossRef] [PubMed]
- Tahir, U.A.; Doros, G.; Kim, J.S.; Connors, L.H.; Seldin, D.C.; Sam, F. Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Sci. Rep. 2019, 9, 8552. [Google Scholar] [CrossRef] [PubMed]
N = 81 | % | |
---|---|---|
Excluded | 17 | |
Patient data analyzed | 64 | |
Age (years), median, range | 69 | 29–95 |
<60 | 12 | 18.8 |
60–64 | 9 | 14.1 |
65–69 | 16 | 25.0 |
70–74 | 5 | 7.8 |
75–79 | 14 | 21.9 |
80–84 | 6 | 9.4 |
85–90 | 0 | 0 |
>90 | 2 | |
Gender | ||
Female | 23 | 35.9 |
Male | 41 | 62.5 |
M (M to F transgender) | 1 | 1.5 |
Disease Type | ||
Amyloidosis (AApoAIV subtype) | 1 | 1.5 |
Hereditary Amyloidosis | 26 | 40.6 |
Light Chain Amyloidosis | 16 | 25 |
Wild-type Amyloidosis | 21 | 32.8 |
Organ involvement | ||
Cardiac | 25 | 39.1 |
Kidney | 6 | 9.4 |
Multiple organ involvement | 19 | 29.7 |
Peripheral neuropathy | 13 | 20.3 |
Pulmonary | 1 | 1.5 |
Original Score | Difference from Normative (Original Score-Normative) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
n | SF36 | 30 s Sit to Stand | TUG | 30 s Sit to Stand: diff | TUG: diff | ||||||
Disease Type | Median | Range | Median | Range | Median | Range | Median | Range | Median | Range | |
Amyloidosis, AApoAIV subtype | 1 | 85 | 12 | 8.38 | −3.2 | 1.08 | |||||
Hereditary Amyloid | 26 | 60 | 20–100 | 11.5 | 4–17 | 9 | 5.9–38.92 | −2.5 | −9.5–3.5 | 1.8 | −1.42–25.42 |
Light Chain Amyloid | 16 | 37.5 | 5–100 | 10 | 7–21 | 10 | 5.98–15.44 | −4 | −7–6.5 | 1.92 | −2.12–7.2 |
Wild Type TTR Amyloid | 21 | 65 | 5–100 | 12 | 7–22 | 10 | 6.2–54.66 | −2.4 | −6–9 | 0.42 | −12.18–47.86 |
p-values: | |||||||||||
Overall | 0.32 | 0.7 | 0.82 | 0.35 | 0.48 | ||||||
Light Chain Amyloid vs. Wild Type | 0.19 | 0.47 | 0.79 | 0.17 | 0.26 | ||||||
Hereditary Amyloid vs. Wild Type | 0.97 | 0.83 | 0.77 | 0.27 | 0.44 | ||||||
Hereditary Amyloid vs. Light Chain | 0.19 | 0.47 | 0.52 | 0.88 | 0.57 | ||||||
n | SF36 | 30 Seconds Sit to Stand | TUG | 30 Seconds Sit to Stand | TUG | ||||||
Organ Involvement | |||||||||||
Cardiac | 25 | 55 | 5–95 | 10 | 7–17 | 10 | 6.4–54.66 | −3.4 | −6.4–3 | 1.9 | −12.18–47.86 |
Non-cardiac | 39 | 60 | 10–100 | 12 | 4–22 | 9 | 5.9–38.92 | −2.5 | −9.5–9 | 1.7 | −9.6–25.42 |
p-value | 0.71 | 0.2 | 0.44 | 0.7 | 0.9 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Redder, E.; Zhao, Q.; Bumma, N.; Kahwash, R.; Vallakati, A.; Campbell, C.; Parikh, S.; Almaani, S.; Freimer, M.; Efebera, Y.; et al. Functional Impairments of Amyloidosis Patients: Physical Therapy Assessment. Hemato 2022, 3, 414-421. https://doi.org/10.3390/hemato3030028
Redder E, Zhao Q, Bumma N, Kahwash R, Vallakati A, Campbell C, Parikh S, Almaani S, Freimer M, Efebera Y, et al. Functional Impairments of Amyloidosis Patients: Physical Therapy Assessment. Hemato. 2022; 3(3):414-421. https://doi.org/10.3390/hemato3030028
Chicago/Turabian StyleRedder, Elyse, Qiuhong Zhao, Naresh Bumma, Rami Kahwash, Ajay Vallakati, Courtney Campbell, Samir Parikh, Salem Almaani, Miriam Freimer, Yvonne Efebera, and et al. 2022. "Functional Impairments of Amyloidosis Patients: Physical Therapy Assessment" Hemato 3, no. 3: 414-421. https://doi.org/10.3390/hemato3030028
APA StyleRedder, E., Zhao, Q., Bumma, N., Kahwash, R., Vallakati, A., Campbell, C., Parikh, S., Almaani, S., Freimer, M., Efebera, Y., & Sharma, N. (2022). Functional Impairments of Amyloidosis Patients: Physical Therapy Assessment. Hemato, 3(3), 414-421. https://doi.org/10.3390/hemato3030028